Health Condition 1: null- rheumatoid arthritis
Conditions
Interventions
Intervention1: stifain Tablet
: Each tablet contains:
1. Maharasanadi Kvatha Formulation 150 mg
2. Yograj guggulu Formulation 100 mg
3. Mahavatvidhwans Ras Formulation 50 mg
4. Ekangvira Rasa Formula
Sponsors
Ayurchem Products Mumbai
Eligibility
Inclusion criteria
Inclusion criteria: CRITERIA FOR DIAGNOSIS:- Presence of any four out of the following seven (Joneâ??s) criteria (according to 1987, revised criteria of American College of Rheumatology) 4 a. Morning stiffness: Stiffness in and around joints lasting one hour before maximal improvement (More than 6 weekâ??s duration). b. Arthritis of three or more joints, at least three joint area, observed by scholar, having pain with soft tissue swelling or joint effusion, not just bony over growth, (more than 6 weeks duration). c. Arthritis of hand joints, at least 1 area in wrist and hand is swollen (more than 6 weeks duration). d. Symmetric arthritis (more than 6 weekâ??s duration). e. Presence of Rheumatoid Nodules f. Serum Rheumatoid factor- positive g. Typical radiographic changes of arthritis on PA view of hand & wrist radiograph that must include erosions or unequivocal bony decalcification, localized in or adjacent to involved joints. Patients fulfilling the diagnostic criteria, of either sex with age between 20 and 60 years (2) Willing and able to participate in the study.
Exclusion criteria
Exclusion criteria: 1) Patients who have developed complications of Rheumatoid Arthritis e.g. severe deformity of joints / bones, pleura-pericardial disease, or else. (2) Patients with poorly controlled Hypertension or with uncontrolled Diabetes Mellitus and having a past history of Atrial Fibrillation, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months. (4) Patients on prolonged medication with corticosteroids, antidepressants, anticholinergics, etc. or any other drugs that may have an influence on the outcome of the study. (5) H/o hypersensitivity to any of the trial drugs or their ingredients. (6) Pregnant/lactating women. (7) Patients having chronicity >10 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the clinical safety and efficacy of Stifain Tablet in the management of Rheumatoid Arthritis (Amavata) Timepoint: 2 months | — |
Secondary
| Measure | Time frame |
|---|---|
| To assess the improvement in physical mobility and quality of life in patientTimepoint: 2 months | — |
Countries
India
Contacts
Public ContactDr Mandip Goyal
Institute for Post Graduate Teaching and Research in Ayurved, Jamnagar
Outcome results
None listed